Therapeutic efficacy of ABT-737, a Bcl-2 inhibitor, in a canine melanoma cell line.

Abstract

The small molecule inhibitor, ABT-737, inhibits Bcl-2 that is overexpressed in many tumor cell lines and, in combination with an anticancer drug, can strongly enhance proapoptotic activity. In the present study, we evaluated the inhibitory activity of ABT-737 on the survival of a canine melanoma cell line (MCM-N1). MCM-N1 cell viability was decreased following 24- and 48-hr culture with ABT-737, depending on ABT-737 concentration, while cell viability was unchanged in controls. ABT-737 synergized with carboplatin to promote cell death. Notably, approximately 50% of MCM-N1 cells survived following culture with 2-4 µg/ml of carboplatin; whereas, less than 20% of MCM-N1 cells survived following culture with ABT-737 (1 mM) plus carboplatin (2-10 µg/ml).

• Authors: Mai Uwano, Rui Kano, Haruhiko Maruyama, Atsuhiko Hasegawa, Hiroshi Kamata
• Journal: The Journal of veterinary medical science (J Vet Med Sci) Vol. 74 Issue 6 Pg. 783-5 (Jun 2012) ISSN: 1347-7439 [Electronic] Japan
• PMID: 22214861 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ABT-737
• Biphenyl Compounds
• Nitrophenols
• Piperazines
• Proto-Oncogene Proteins c-bcl-2
• Sulfonamides
• Carboplatin

Topics

• Animals
• Biphenyl Compounds (pharmacology)
• Carboplatin (pharmacology)
• Cell Line, Tumor
• Cell Survival (drug effects)
• Dog Diseases (drug therapy)
• Dogs
• Dose-Response Relationship, Drug
• Melanoma (drug therapy, veterinary)
• Nitrophenols (pharmacology)
• Piperazines (pharmacology)
• Proto-Oncogene Proteins c-bcl-2 (antagonists & inhibitors)
• Sulfonamides (pharmacology)